Skip to content

6-gingerol enriched preoperative carbohydrate loading for post-embolization syndrome prevention in HCC patients

Efficacy of 6-gingerol preoperative carbohydrate loading on post embolization syndrome prevention in patients with hepatocellular carcinoma undergoing trans-arterial chemoembolization: A randomized controlled trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20260224003
Enrollment
84
Registered
2026-02-24
Start date
2026-02-02
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma Transarterial Chemoembolization Preoperative Carbohydrate Loading Post-Embolization Syndrome Enhanced Recovery After Surgery Insulin Resistance Blood Glucose Randomized Controlled Trial Quality of Life Nutritional Support Liver Neoplasms Carbohydrate Loading Embolization, Therapeutic Metabolic Response Patient Comfort Treatment Outcome

Interventions

Participants in the intervention group will receive a preoperative carbohydrate loading beverage consisting of a carbohydrate solution providing approximately 50 grams of carbohydrates in a volume of
Experimental Other,No Intervention No treatment
Carbohydrate loading arm,Control

Sponsors

Faculty of Medicine, Prince of Songkla University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Diagnosis of hepatocellular carcinoma according to accepted clinical or radiological criteria. 2. Scheduled to undergo transarterial chemoembolization as part of standard clinical care. 3. Age >= 18 years old

Exclusion criteria

Exclusion criteria: 1. Patients undergoing trans-arterial chemoembolization outside regular hospital working hours. 2. Diabetes mellitus with hemoglobin A1c greater than 8 percent. 3. Fasting plasma glucose level greater than 300 milligrams per deciliter at initial assessment. 4. Type 1 diabetes mellitus. 5. Symptomatic gastroesophageal reflux disease requiring ongoing treatment. 6. History of allergy or hypersensitivity to any component of the carbohydrate beverage. 7. History of aspiration. 8. Child-Pugh classification class B8 or higher. 9. Patients undergoing repeated trans-arterial chemoembolization who have previously participated in this study.

Design outcomes

Primary

MeasureTime frame
Post embolization syndrome 4 to 6 hours after transarterial chemoembolization, postoperative day 1 morning, and 48 hours after the procedure Clinical diagnostic criteria including body temperature, abdominal pain, nausea or vomiting, liver enzyme levels, and white blood cell count

Secondary

MeasureTime frame
Blood glucose level Pre procedure, 4 to 6 hours after transarterial chemoembolization, and postoperative day 1 morning Venous blood glucose measurement,Insulin resistance Pre procedure and postoperative day 1 morning Fasting insulin and glucose based calculation,Pain severity 4 to 6 hours after transarterial chemoembolization and postoperative day 1 morning Visual analog scale pain score,Quality of life Pre procedure and 48 hours after the procedure Five level EuroQol questionnaire,Nutritional status Pre procedure and postoperative day 1 morning Body mass index and clinical nutritional assessment

Countries

Thailand

Contacts

Public ContactChaitong Churuangsuk

Prince of Songkla University

chaitong.c@psu.ac.th0959414597

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026